<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Roivant Sciences Ltd — News on 6ix</title>
    <link>https://6ix.com/company/roivant-sciences-ltd</link>
    <description>Latest news and press releases for Roivant Sciences Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/roivant-sciences-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b9a778dffbe2df1158af.webp</url>
      <title>Roivant Sciences Ltd</title>
      <link>https://6ix.com/company/roivant-sciences-ltd</link>
    </image>
    <item>
      <title>Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-10</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-10</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound</description>
    </item>
    <item>
      <title>Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/priovant-expands-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-12</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/priovant-expands-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-12</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound</description>
    </item>
    <item>
      <title>New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/new-england-journal-of-medicine-publishes-positive-phase-3-valor-trial-results-of-brepocitinib-in-dermatomyositis</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/new-england-journal-of-medicine-publishes-positive-phase-3-valor-trial-results-of-brepocitinib-in-dermatomyositis</guid>
      <pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
      <description>The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30</description>
    </item>
    <item>
      <title>Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-genevant-sciences-and-arbutus-biopharmas-dollar225-billion-global-settlement-with-moderna</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-genevant-sciences-and-arbutus-biopharmas-dollar225-billion-global-settlement-with-moderna</guid>
      <pubDate>Tue, 03 Mar 2026 21:15:00 GMT</pubDate>
      <description>Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted</description>
    </item>
    <item>
      <title>Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/priovant-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-brepocitinib-in-dermatomyositis</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by</description>
    </item>
    <item>
      <title>Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-positive-phase-2-120000706</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-announces-positive-phase-2-120000706</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 GMT</pubDate>
      <description>Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P&lt;0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the t</description>
    </item>
    <item>
      <title>Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/pulmovant-announces-completion-of-enrollment-in-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/pulmovant-announces-completion-of-enrollment-in-the-phase-2-phocus-study-of-mosliciguat-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 GMT</pubDate>
      <description>PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment</description>
    </item>
    <item>
      <title>Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/priovant-announces-positive-phase-2-results-for-brepocitinib-in-cutaneous-sarcoidosis-cs</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/priovant-announces-positive-phase-2-results-for-brepocitinib-in-cutaneous-sarcoidosis-cs</guid>
      <pubDate>Fri, 06 Feb 2026 05:00:00 GMT</pubDate>
      <description>Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a</description>
    </item>
    <item>
      <title>Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/immunovant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/immunovant-to-report-financial-results-for-the-third-quarter-ended-december-31-2025-and-provide-business-update-on-friday-february-6-2026</guid>
      <pubDate>Fri, 23 Jan 2026 22:25:00 GMT</pubDate>
      <description>DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News &amp; Events” in the Investors section of the Imm</description>
    </item>
    <item>
      <title>Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-report-financial-results-third-211500714</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-report-financial-results-third-211500714</guid>
      <pubDate>Fri, 23 Jan 2026 21:15:00 GMT</pubDate>
      <description>BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events &amp; Prese</description>
    </item>
    <item>
      <title>Immunovant Announces Pricing of $550 Million Common Stock Financing</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/immunovant-announces-pricing-of-dollar550-million-common-stock-financing</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/immunovant-announces-pricing-of-dollar550-million-common-stock-financing</guid>
      <pubDate>Thu, 11 Dec 2025 06:29:00 GMT</pubDate>
      <description>Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable</description>
    </item>
    <item>
      <title>Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-highlights-continued-pipeline-progress-and-outlook-companys-next-phase-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-highlights-continued-pipeline-progress-and-outlook-companys-next-phase-growth</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next</description>
    </item>
    <item>
      <title>Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-reports-financial-results-second-quarter-ended-september-30-2025-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-reports-financial-results-second-quarter-ended-september-30-2025-and-provides</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second</description>
    </item>
    <item>
      <title>Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025</guid>
      <pubDate>Mon, 27 Oct 2025 20:10:00 GMT</pubDate>
      <description>NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News &amp; Events” in the Investors section of the Immunovant websit</description>
    </item>
    <item>
      <title>Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-report-financial-results-second-quarter-ended-september-30-2025-and-provide</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-report-financial-results-second-quarter-ended-september-30-2025-and-provide</guid>
      <pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
      <description>BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call</description>
    </item>
    <item>
      <title>Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-and-priovant-announce-positive-phase-3-valor-study-results-brepocitinib-52</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-and-priovant-announce-positive-phase-3-valor-study-results-brepocitinib-52</guid>
      <pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
      <description>Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint</description>
    </item>
    <item>
      <title>Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-named-fortune-media-and-great-place-works-2025-best-workplaces-biopharma-list</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-named-fortune-media-and-great-place-works-2025-best-workplaces-biopharma-list</guid>
      <pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
      <description>BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV)</description>
    </item>
    <item>
      <title>Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/pulmovant-receives-orphan-drug-designation-in-japan-for-mosliciguat-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/pulmovant-receives-orphan-drug-designation-in-japan-for-mosliciguat-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild</guid>
      <pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
      <description>Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternativeA global Phase 2 PHocus study of mosliciguat in PH-ILD is currently ongoing and will be highlighted in a study-in-progress poster at the European Respiratory Society International Congress 2025 on September 28th WALTHAM, Mass., Sept. 04, 2025 (</description>
    </item>
    <item>
      <title>Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves&apos; Disease Patients</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-unveils-durability-and-treatment-free-six-month-remission-data-potential</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-unveils-durability-and-treatment-free-six-month-remission-data-potential</guid>
      <pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
      <description>First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up</description>
    </item>
    <item>
      <title>Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update</title>
      <link>https://6ix.com/company/roivant-sciences-ltd/news/roivant-reports-financial-results-first-quarter-ended-june-30-2025-and-provides</link>
      <guid isPermaLink="true">https://6ix.com/company/roivant-sciences-ltd/news/roivant-reports-financial-results-first-quarter-ended-june-30-2025-and-provides</guid>
      <pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
      <description>BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first</description>
    </item>
  </channel>
</rss>